Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2006-10-05
2008-09-23
Blanchard, David J. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S300000, C424S185100, C435S320100, C435S325000, C435S006120, C435S069300, C536S023100
Reexamination Certificate
active
07427660
ABSTRACT:
Tumor antigen inducing and/or activating HLA-A2-restricted tumor-specific cytotoxic T lymphocytes that is activated by recognizing HLA-A2 and a tumor antigen peptide, and a peptide or polypeptide derived from the tumor antigen, a polynucleotide encoding the peptide or a complementary strand polynucleotide thereof, a transformant comprising a recombinant vector which comprises the polynucleotide are provided.
REFERENCES:
patent: 5840839 (1998-11-01), Wang et al.
patent: 5874231 (1999-02-01), Sonenberg et al.
patent: 5936078 (1999-08-01), Kuga et al.
patent: 2000-189168 (2000-07-01), None
patent: WO 97/21807 (1997-06-01), None
patent: WO 01/12660 (2001-02-01), None
Gritzapis et al. British Journal of Cancer, 2005. 92:72-79.
Zaks and Rosenberg. Cancer Research, 1998. 58:4802-4808.
Pinol-Roma et al. Journal of Cell Biology, 1989. 109:2575-2587.
Hida, N. et al., “A Simple Culture Protocol to Detect Peptide-Specific Cytotoxic T Lymphocyte Precursors in the Circulation,”Cancer Immunol Immunother(2002) 51: 219-228.
Janeway, C. et al.,Immuno Biology, 6thEdition, pp. 124, 125, 174, 175, 330-33, 346-349.
Mine, T. et al., “Humoral Responses to Peptides Correlate with Overall Survival in Advanced Cancer Patients Vaccinated with Peptides Based on Pre-existing, Peptide-Specific Cellular Responses,”Clinical Cancer Research, vol. 10, Feb. 1, 2004, pp. 1-9.
Noguchi M. et al., “Phase I trial of patient-oriented vaccination in HLA-A2-positive patients with metastatic hormone-refractory prostate cancer,”Cancer Sci., Jan. 2004, vol. 95, No. 1, 77-84.
Noguchi, M., “Immunological Monitoring During Combination of Patient-Oriented Peptide Vaccination and Estramustine Phosphate in Patients With Metastic Hormone Refractory Prostate Cancer,”The Prostate, 60:32-45(2004).
Mochizuki, K., et al., “Immunological evaluation of vaccination with Pre-Designated Peptides Frequently Selected as Vaccine Candidates in a Individualized Peptide Vaccination Regimen,”Intn'l J. of Oncology, 25:121-131 2004.
Rammensee et al, “MHC Ligands and Peptide Motifs: First Listing”Immunogenetics; 41:178-228 (1995).
Maeda et al., “Detection of peptide-specific CTL-precursors in peripheral blood lymphocytes of cancer patients,”British Journal of Cancer, 87:7:796-804 (Sep. 23, 2002).
Dermer, G.B., “Another Anniversary for the War on Cancer,”BioTechnology, 1994, 12:320.
Freshney, “Culture of Animal Cells,”A Manual of Basic Technique, Alan R. Liss Inc., 1983 NY.
Riott et al., “Antigen Recognition,”Immunology, 4th Ed., 1996, Mosby, p. 7, 9-7, 11).
Ito, Masaaki, et al. “Molecular Basis of T Cell-Mediated Recognition of Pancreatic Cancer Cells”Cancer Research61, 238-2046, Mar. 1, 2001.
Shain, Urur, et al. “Human neoplasms elicit multiple specific immune responses in the autologous host”Pro. Natl., Acad. Sci USA, vol. 92, pp. 11810-11813, Dec. 1995 Immuniology.
Yang, Damu, et al. “Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted Cytotoxic T Lymphocytes in Cancer Patients”Cancer Research59, 4056-4063, Aug. 15, 1999.
Kikuchi, Megumi, et al., “Identification of Sart-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T Lymphocytes”Int'l J. Cancer, 81, 459-466 (1999).
Gomi, Shinya, et al. “A cyclophilin B gene encodes antigenic epitopes recognized by HLA-A24-restricted and tumor-specific CTLs”The Journal of Immunologypp. 4994-5004.
Shichijo, Shigeki, et al. “A Gene Encoding Antigenic peptides of Human Squamous Cell Carcinoma Recognized by Cytotoxic T Lymphocytes”J. Exp. Med. vol. 187, No. 3, Feb. 2, 1998 277-288.
Nakatsura, Tetsuya et al. “Gene Cloning of Immunogenic antigens Overexpressed in Pancreatic Cancer”Biochemical and Biophysical Research Communication281, 936-944 (2001).
Yamada, Akira, et al. “Study of HLA class I restriction and the direction antigens of cytotoxic T lymphocytes at the tumor sites of ovarian cancer”Cancer Immunol. Immunother(1999) 48: 147-152.
Peiper, Matthias, et al. “Pancreatic Cancer Associated Ascites-Derived CTL Recognize a Nine-Amino-Acid Peptide GP2 Derived from HER2
ue”Anticancer Research19: 2471-2475 (1999).
Pinol-Roma, Scrafin, et al. “A novel heterogeneous nuclear RNP protein with a unique distribution on nascent transcripts”The Journal of Cell Biology, vol. 109 (No. 6, Pt. I) Dec. 1989 pp.. 2575-2587.
Bodey, B., et al., “Failure of Cancer Vaccines: The Significant Limitations of the Approach to Immunotherapy,”Anticancer Research20:2665-2676, 2000.
Cox, A.L., et al., “Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell Lines,”Science, 264: 5159, 716-719, Apr. 29, 1994.
Ezzell, C., “Cancer ‘Vaccines’: An Idea Whose Time Has Come?,”Journal of NIH Research, 7:46-49, Jan. 1995.
Spitler, L.E., “Cancer Vaccines: The Interferon Analogy,”Cancer Biotherapy, 10: 1-3, 1995.
Boon, T., “Toward A Genetic Analysis of Tumor Rejection Antigens,”Advances in Cancer Research, 1992, 58: 177-210.
Arceci, R.J., “The potential for antitumor vaccination in acut myelogenous leukemia,”Journal of Molecular Medicine, 76: 80-93, 1998.
Lee, K.H. et al. “Increased Vaccine-Specific T Cell Frequency After Peptide-Based Vaccination Correlates with Increased Susceptibility to In Vitro Stimulation But Does Not Lead to Tumor Regression,”Journal of Immunology, 163: 6292-6300, 1999.
Zaks, T.Z.,et al, “Immunization with a Peptide Epitope (p. 369-377) from HER-2
ew Leads to Peptide-specific Cytotoxic T Lymphocytes That Fail to Recognize HER-2
ew+ Tumors,”Cancer Research, 58: 4902-4908, Nov. 1, 1998.
Gao, P., et al, Tumor Vaccination That Enhances Antitumor T-Cell Responses Does Not Inhibit the Growth of Established Tumors Even in Combination With Interleukin-12 Treatment: The Importance of Inducing Intramoral T-Cell Migration,:Journal of Immunotherapy, 23: 643-653, 2000.
Hu, X., et al, “Enhancement of Cytolytic T Lymphocyte Precursor Frequency in Melonoma Patients following immunization with the MAGE-1 Peptide Loaded Antigen Presenting Cell-based Vaccine,”Cancer Research, 56: 2479-2483, Jun. 1, 1996.
Jaeger, E., et al., “Generation of Cytotoxic T-Cell Responses with Synthetic Melonoma-Associated Peptides In Vivo: Implications for Tumor Vaccines with Melanoma-Associated Antigens”,International Journal of Cancer, 66: 162-169, 1996.
Mukherji, B., et al., “Induction of antigen-specific cytolytic T cells in situ 1 human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells,”Proceedings of the National Academy of Sciences USA, 92: 8078-8082 (Aug. 1995).
Gura, T., “Systems for Identifying New Drugs Are Often Faulty,”Science, 278: 1041-1042, Nov. 7, 1997.
Kanneganti G.K., et al. “The 160-kD subunit of human cleavage-polyadenylation specificity factor coordinates pre-mRNA 3'-end formation”Genes&Development9: 2672-2683 1995.
Nagase, Takahiro, et al. “Prediction of the Coding Sequences of Unidentified human genes. IV. The coding sequences of 40 new genes (KIAA0121-KIAA0160) Deduced by Analysis of cDNA Clones from Human Cell Line KG-1)”DNA Research2, 167-174, 1995.
International Search Report PCT/JP01/06526.
International Preliminary Examination Report PCT/JP01/06526.
Blanchard David J.
Green Peptide Co., Ltd.
Tungaturthi Parithosh K.
LandOfFree
Tumor antigen does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor antigen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor antigen will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3981223